Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-05-26
1997-01-28
Elliott, George C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424 9464, 435 691, 435 692, 435 696, 514 2, 514 8, 530384, 530395, A61K 3836, A61K 3848, A61K 3514, C07K 14745
Patent
active
055977995
ABSTRACT:
Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be conveniently prepared using recombinant techniques.
REFERENCES:
patent: 4337244 (1982-06-01), Smith
patent: 5120537 (1992-06-01), Esmon et al.
patent: 5278144 (1994-01-01), Wolf
Neuenschwander et al. "The Use of Acetylated Factor X to Prevent Feedback Activation of Factor VIII during Factor X Activation: A Tool for Kinetic Studies" Anal Biochem 184 347-352 1990.
Fung et al. "Characterization of an Almost Full-Length cDNA Coding for Human Blood Coagulation Factor X" Proc. Natl. Acad. Sci. 82:3591-3595 1985.
Bernardi, et al., "Partial Gene Deletion in a Family with Factor X Deficiency" Blood, vol. 73, No. 8, 2123-2127 (1989).
Cassels, et al., "The Interaction of Streptokinase Plasminogen Activator Complex, Tissue-Type Plasminogen Activator, Urokinase and their Acylated Derivatives with Fibrin and Cyanogen Bromide Digest of Fibrinogen" Biochem. J. 247, 395-400 (1987).
Crabbe, et al., "Acylated Plasminogen-Streptokinase Activator Complex: A New Approach to Thrombolytic Therapy" Pharmacotherapy, vol. 10, No. 2, 115-126 (1990).
Davie, "The Blood Coagulation Factors: Their cDNAs, Genes, and Expression" Plasma Coagulation Factors, 242-267.
DiScipio, et al., "Activation of Human Factor X (Stuart Factor) by a Protease from Russell's Viper Venom" Biochemistry, vol. 6, No. 24, 5253-5260 (1977).
Dunwiddie, et al., "Antistasin, a Leech-Derived Inhibitor of Factor Xa" The Journal of Biological Chemistry, vol. 264, No. 26, 16694-16699 (1989).
Etingin, et al., "Viral Activation of the Coagulation Cascade: Molecular Interactions at the Surface of Infected Endothelial Cells" Cell, vol. 61, 657-662 (1990).
Fair, et al., "Isolation and Characterization of the Factor X Friuli Variant" Blood, vol. 73, No. 8, 2108-2116 (1989).
Fears, "Development of Anisoylated Plasminogen-Streptokinase Activator Complex from the Acyl Enzyme Concept" Seminars in Thrombosis and Hemostasis-vol. 15, No. 2, 129-139 (1989).
Fears, et al., "The Protective Effect of Acylation on the Stability of Anisoylated Plasminogen Streptokinase Activator Complex in Human Plasma" Drugs 33 (Suppl. 3, 57-63 (1987).
Furie, et al., "The Molecular Basis of Blood Coagulation" Cell, vol. 53, 505-518 (1988).
Girard, et al., "Functional Significance of the Kunitz-Type Inhibitory Domains of Lipoprotein-Associated Coagulation Inhibitor" Nature, vol. 338, 518-520 (1989).
Girard, et al., "Inhibition of Factor Vlla-Tissue Factor Coagulation Activity by a Hybrid Protein" Science, vol. 248, 1421-1424 (1990).
Hassan, et al., "Multiple Polymorphic Sites in Factor X Locus" Blood, vol. 71, No. 5, 1353-1356 (1988).
Hoover, et al., "The Adhesive Interaction between Polymorphonuclear Leukocytes and Endothelial Cells in Vitro" Cell, vol. 14, 423-428 (1978).
Husten, et al., "The Active Site of Blood Coagulation Factor Xa" The Journal of Biological Chemistry, vol. 262, No. 27, 12953-12961 (1987).
Krishnaswamy, et al., "Prothrombinase Complex Assembly" The Journal of Biological Chemistry, vol. 263, No. 8, 3823-3834 (1988).
Levine, "Clinical Manifestations and Therapy of Hemophilias A and B" Plasma Coagulation Factors, 97-111.
Nesheim et al., "The Contribution of Bovine Factor V and Factor Va to the Activity of Prothrombinase" The Journal of Biological Chemistry, vol. 254, No. 21, 10952-10962 (1979).
Nesheim, et al., "Cofactor Dependence of Factor Xa Incorporation into the Prothrombinase Complex" The Journal of Biological Chemistry, vol. 256, No. 13, 6537-6540 (1981).
Reddy, et al., "Molecular Characterization of Human Factor X.sub.San Antonio " Blood, vol. 74, No. 5, 1486-1490 (1989).
Skogen, et al., "Comparison of Coagulation Factor Xa and Des-(1-44) Factor Xa in the Assembly of Prothrombinase" The Journal of Biological Chemistry, vol. 256, No. 4, 2306-2310 (1984).
Steinberg, et al., "Activation of Factor X" Plasma Coagulation Factors, 112-119.
St urzebecher, et al., "Stable Acyl-Derivatives of Tissue-Type Plasminogen Activator" Thrombosis Research 47, 699-703 (1987).
Watzke, et al., "Molecular Defect (Gla.sup.+14 .fwdarw.Lys) and its Functional Consequences in a Hereditary Factor X Deficiency (Factor X Vorarlberg") The Journal of Biological Chemistry, vol. 285, No. 20, 11982-11989 (1990).
Waxman, et al., "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa" Science, vol. 248, 593-596 (1990).
Ehrlich et al., Journal of Biological Chemistry, vol. 264, pp. 14298-14304 (1989).
COR Therapeutics Inc.
Degen Nancy J.
Elliott George C.
LandOfFree
Recombinant agents affecting thrombosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant agents affecting thrombosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant agents affecting thrombosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-941506